



Online Supplementary Material

Could the Inflation Reduction Act Maximum Fair Price Hurt Patients? *JHEOR*. 2024;11(2):??-??. [doi:10.36469/jheor.2024.125251](https://doi.org/10.36469/jheor.2024.125251)

Table S1: Calculated Copay Costs for Medicare Part D Apixaban and Rivaroxaban Prescriptions Managed by the 3 Largest PBMs (2023 \$US)

Table S2: Differences in Midpoint Copay Costs If Apixaban and Rivaroxaban Moved to Tier 6 (2023 \$US)

Figure S1: Relationship Between Copay Amounts and Treatment Abandonment

Figure S2: Present and Predicted Increases in Treatment Abandonment

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1. Calculated Copay Costs for Medicare Part D Apixaban and Rivaroxaban Prescriptions Managed by the 3 Largest PBMs (2023 \$US)							
Drug	PBM	Calculated Copay Costs (in Million 2023 \$US)					
		2023			If All Moved to Tier 6		
		Min	Mid	Max	Min	Mid	Max
Apixaban (Eliquis)	CVS	347	532	723	460	705	958
	ORx	225	351	482	333	512	695
	ESI	181	276	374	195	301	408
	Top 3 PBMs	753	1159	1579	988	1518	2061
Rivaroxaban (Xarelto)	CVS	148	221	296	194	287	384
	ORx	83	127	172	130	192	257
	ESI	66	98	132	78	116	155
	Top 3 PBMs	297	446	590	402	595	796

The formulas used to derive these values are described in the Modeling section.
Abbreviations: CVS Caremark, CVS; Express Scripts International, ESI; ORx, Max, maximum; Min, minimum; Mid; midpoint; ORx, Optum Rx; PBM, pharmacy benefit manager.

Table S2. Differences in Midpoint Copay Costs If Apixaban and Rivaroxaban Moved to Tier 6 (2023 \$US)				
Drug	PBM	Calculated Copay Costs (in Million 2023 \$US)		Difference (All Tier 6 vs 2023 Actual)
		2023	All Tier 6	
Apixaban (Eliquis)	CVS	532	705	173
	ORx	351	512	161
	ESI	276	301	25
	Top 3 PBMs	1159	1518	359
Rivaroxaban (Xarelto)	CVS	221	287	66
	ORx	127	192	65
	ESI	98	116	18
	Top 3 PBMs	446	595	149

The formulas used to derive these values are described in the Modeling section.
Abbreviations: CVS Caremark, CVS; Express Scripts International, ESI; ORx, Optum Rx; PBM, pharmacy benefit manager.

Figure S1. Relationship Between Copay Amounts and Treatment Abandonment





Figure S2. Present and Predicted Increases in Treatment Abandonment



Abbreviations: CVS, CVS Caremark; ESI, Express Scripts International; ORx, Optum Rx.